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Abstract
Background: Latest Next Generation Sequencing technologies opened the way to a novel era of genomic studies,
allowing to gain novel insights into multifactorial pathologies as cancer. In particular gene fusion detection and
comprehension have been deeply enhanced by these methods. However, state of the art algorithms for gene fusion
identification are still challenging. Indeed, they identify huge amounts of poorly overlapping candidates and all the
reported fusions should be considered for in lab validation clearly overwhelming wet lab capabilities.
Results: In this work we propose a novel methodological approach and tool named FuGePrior for the prioritization of
gene fusions from paired-end RNA-Seq data. The proposed pipeline combines state of the art tools for chimeric
transcript discovery and prioritization, a series of filtering and processing steps designed by considering modern
literature on gene fusions and an analysis on functional reliability of gene fusion structure.
Conclusions: FuGePrior performance has been assessed on two publicly available paired-end RNA-Seq datasets: The
first by Edgren and colleagues includes four breast cancer cell lines and a normal breast sample, whereas the second
by Ren and colleagues comprises fourteen primary prostate cancer samples and their paired normal counterparts.
FuGePrior results accounted for a reduction in the number of fusions output of chimeric transcript discovery tools that
ranges from 65 to 75% depending on the considered breast cancer cell line and from 37 to 65% according to the
prostate cancer sample under examination. Furthermore, since both datasets come with a partial validation we were
able to assess the performance of FuGePrior in correctly prioritizing real gene fusions. Specifically, 25 out of 26
validated fusions in breast cancer dataset have been correctly labelled as reliable and biologically significant. Similarly,
2 out of 5 validated fusions in prostate dataset have been recognized as priority by FuGePrior tool.
Keywords: Gene fusions, Gene fusion prioritization, Chimeric transcript discovery tools, RNA-sequencing
Background
The impact of somatic mutations in cancer onset, pro-
gression and response to treatment has been widely inves-
tigated in the last century [1, 2]. Furthermore, special
attention has been devoted to the identification of the
so called driver mutations that, differently from passen-
ger mutations, have been found to be responsible for
abnormal cell proliferation and cancer development [3].
In an effort to provide complete characterization of the
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mutational landscape underlying different cancer types,
several consortia as The Cancer Genome Atlas (TCGA)
[4] or the Breast Cancer Surveillance Consortium (BCSC)
[5] have been recently established. These projects bene-
fited of recent advances in genome analysis technologies
among which Next Generation Sequencing (NGS).
The analysis of the nowadays available mutational data,
confirms the high variability and heterogeneity proper of
cancers and cancer subtypes. Furthermore, several muta-
tions have been found to be shared by different neoplasia
and only some alterations seem to be disease-specific
or even pathognomonic. Among mutations gene fusions
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can be considered a typical example of pathognomonic
alterations. Thus, their identification and characteriza-
tion have been considered, and still are believed to be
fundamental for clinical purposes [6]. As an example,
TMPRSS2-ERG fusion has been exploited for prostate
cancer screening purposes [7], fusions involving MLL
gene have been considered for Acute Myeloid Leukemia
(AML) treatment stratification [8], RUNX1-RUNX1T1
fusion has been used for AML diagnosis according to
World Health Organization (WHO) classifications [9],
and PML-RARA fusion for monitoring minimal residual
disease after treatment in adult AML [10].
The emergence of NGS technologies some decades
ago, particularly RNA-Sequencing (RNA-Seq), gave a
further decisive boost to the comprehension of gene
fusion role in cancer. Indeed, differently from previous
guided approaches (e.g., banding analyses, fluorescence
in situ hybridization, array based-experiments), RNA-Seq
allowed to identify fusions in a single experiment with-
out any a priori knowledge on the cytogenetic features
of neoplastic cells. The power of this approach becomes
evident by considering that the 90% of gene fusions dis-
covered in the last 5 years have been identified by NGS
data analyses [6]. Furthermore, clinical detection of gene
fusions is progressively shifting towards RNA-Seq assays
(e.g., FoundationOneHeme assay) and an increasing num-
ber of case studies is reporting on clinical responses of
patients treated with drugs after gene fusion detection
with such assays [11–14].
These considerations explain the plethora of tools that,
since late 2010, have been developed for the detection of
gene fusions from RNA-Seq data, most of which rely on
paired-end reads [15]. However, as widely discussed in
[16], several challenges are still associated to these meth-
ods. Besides the considerable amount of time and compu-
tational power required for sample processing, these tools
output lists of fusions that generally poorly overlap and
that are plagued with a huge amount of false positive pre-
dictions. Furthermore, the set of filters implemented by
these tools to reduce the number of candidates, accounts
for reduced sensitivity, potentially causing the loss of real
candidates.
To overcome these drawbacks the union of gene fusion
lists from different tools should be considered for further
analyses. However, temporal and economic constraints
make it unfeasible to validate through Polymerase Chain
Reaction (PCR) the whole set of fusions from different
gene fusion detection tools. Furthermore, the design and
implementation of ad-hoc experiments for the functional
validation of chimeric transcripts is a complex, expen-
sive and time consuming task that limits once again the
number of fusions that can be deepened. In the light
of these considerations it seems clear the need for ad-
hoc pipelines to shrink down the list of candidates from
chimeric transcript discovery tools, thus focusing on a
reduced set of highly reliable fusions with a potential
driver impact into the disease.
To this aim we propose a novel computational approach
and tool named FuGePrior for the prioritization of gene
fusions from paired-end RNA-Seq data. Specifically, the
implemented methodology exploits a set of processing
and filtering stages to lower the number of fusions from
chimeric transcript discovery tools. These filters have
been designed by considering information provided by
currently available chimeric transcript discovery tools
(e.g., number of supporting reads, gene fusion break-
points) and modern literature concerning gene fusions.
Furthermore, to focus on those fusions with a greater
oncongenic driver potential, the driver probability scores
provided by two different Machine Learning (ML) algo-
rithms are evaluated in a further filtering stage.
Considering the implementation, FuGePrior tool has
been developed in Python programming language and
can be run downline of all gene fusion detection tools
having an output compatible with Pegasus [17] input
specifications. Users can easily trigger FuGePrior run to
satisfy their requirements as detailed in the “Testing pro-
cedure” subsection.
FuGePrior has been tested on two publicly available
paired-end RNA-seq datasets respectively from Edgren
and colleagues [15] and Ren and colleagues [18]. The first
one includes four breast cancer cell lines and a normal
sample, whereas the second comprises fourteen primary
prostate cancer samples and their matched adjacent nor-
mal tissues. Both datasets come with a partial in lab
validation that has been exploited to prove the strength
of the proposed approach in correctly prioritizing real
chimeric transcripts.
Implementation
FuGePrior tool consists of a series of filtering and prior-
itization steps that are applied sequentially to the union
list of chimeric candidates from Chimerascan [19], deFuse
[20] and a third chimeric transcript discovery tool selected
by the user. The unique limitation on the choice of this
last algorithm is the compatibility of its output with Pega-
sus tool [17] input format. The compulsory adoption of
both Chimerascan and deFuse has been induced by their
wide and well assessed use in current researches and by
the goodness of the performance that they achieved on
real datasets [16].
All the steps constituting FuGePrior pipeline are sum-
marized in the scheme of Fig. 1 and detailed in the follow-
ing. In the workflow, hexagonal shapes account for tasks
executed by ad-hoc developed programs, the grey rect-
angular ones refer to tasks implemented by state of the
art tools and irregular shapes represent output files. In
details, yellow, light green and light blue shapes report on
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Fig. 1 FuGePrior pipeline. The workflow reports on the prioritization and filtering stages implemented by FuGePrior tool. Hexagonal shapes account
for tasks performed by ad-hoc developed programs, the grey rectangular ones refer to those tasks performed by state of the art tools and irregular
shapes represent output files. Yellow, light green and light blue shapes, report on deFuse, ChimeraScan and MapSplice output respectively. Orange
shapes identify the intermediate outputs
the N output files from deFuse, ChimeraScan and a third
gene fusion detection tool, with N equal to the number of
samples under investigation. Orange shapes identify the
intermediate outputs, whereas the pink ones account for
the final output files. Furthermore, each task is labelled in
the diagram and in the text with a progressive upper case
letter.
First of all, fusions are annotated using Pegasus tool
(A, first phase). The input for Pegasus run is consti-
tuted by the list of gene fusions identified by the three
chimeric transcript discovery tools in the samples under
investigation. ChimeraScan and deFuse outputs can be
processed by Pegasus without the need for substantial
file formatting operations. Conversely, gene fusion data
from the third tool has to be opportunely elaborated
to be analysed by Pegasus. It is worth noting that this
elaboration can be performed on most of chimeric tran-
script discovery tool outputs, thus allowing FuGePrior
to postprocess data from a plethora of gene fusion dis-
covery tools. Details are reported in the “Testing proce-
dure” subsection. By using ENSEMBL gene annotations
[21], Pegasus reconstructs the nucleotide sequence of each
fusion. This activity is performed by considering, for each
fusion, all the transcripts from the two partner genes that
account for the identified breakpoints. Thus, each fusion
can be described by more than a nucleotide sequence.
Based on these sequences, Pegasus assesses the preserva-
tion of the reading frame, derives the amino acid sequence
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of the chimeric protein and evaluates the conservation or
loss of the protein functional domains within the part-
ner genes (by interrogating UniProt Web Service [22]).
The adoption of Pegasus at the beginning of the pipeline
is justified by the need for aggregated and standardized
gene fusion information. Indeed, the internal database
structure of Pegasus, allows each fusion to be described
by the same number and kind of data. This data is par-
tially retrieved from gene fusion detection tool outputs
(e.g., number of supporting reads) and partially elaborated
after ENSEMBL and UNIPROT database interrogation
(e.g., gene fusion sequences, amino acid sequences, read-
ing frame, conserved and lost protein domains). It is worth
noting that the common repository embedded in Pega-
sus, accounts for the identification of fusion candidates
shared by more than a sample. This information can be
exploited by users to distinguish between the so called pri-
vate fusions (i.e., fusions occurring in a unique sample)
and shared fusions (i.e., fusions occurring in more than a
sample).
The aggregated output from Pegasus (a unique file
containing all the annotated fusions from different tools
in different samples) is then elaborated to label fusions
according to the sample (one or more) in which they have
been found and the tool (one or more) responsible for
their identification (B). Since this step, fusions will be
analysed in a sample-centered manner. Thus, at the end of
FuGePrior run, users will be provided with a result file for
each of the analysed sample. In these files, each fusion is
described by a series of information (e.g., number of sup-
porting reads, driver score probabilities, list of samples in
which the fusion has been found) that will make easier the
selection of a set of fusions for further in lab investigation.
As pointed out in [16, 23], gene fusion detection tools
provide in output poorly overlapping results due to their
non inclusive nature. As alreadymentioned, this is the rea-
son for the adoption of more than a tool for gene fusion
discovery and for the choice of considering the union and
not the intersection of predictions from different tools.
Nevertheless, it is important to annotate fusions iden-
tified by more than a tool because they could be with
higher probability real fusions. Furthermore, we experi-
mentally proven that a tool can identify the same fusion
within a sample by using different supporting reads. Such
events are identified and labelled in FuGePrior output
files (C).
Then, those candidates involving unannotated partner
genes are removed from the list of fusions reported for
each sample (D). Indeed, being the function of these genes
not assessed yet, it is not possible to hypothesize a role
of the fusion into the pathology and to estimate a driver
probability for the same.
The identification of gene fusions in non-neoplastic tis-
sues [24–26] led to the design of the next filtering stage
since suggesting the existence of fusions that do not have
a pathogenetic role. Fusion detection is performed in
healthy samples from the same tissue of neoplastic sam-
ples by using the tools already exploited for gene fusion
discovery in tumor samples (E). Those fusions identified
in neoplastic samples that are shared by at least a healthy
sample are removed from the list of priority fusions
because with high probability they are not responsible for
tumor onset and progression.
Later, fusions supported by at least 1 split read (i.e.,
reads harbouring within their sequences the fusion break-
points) are selected from the list of gene fusions (F).
Indeed, the presence of these reads, by allowing the accu-
rate reconstruction of the gene fusion sequence, accounts
for the possibility to validate the fusion throw PCR-based
experiments.
The selected fusions are then formatted conveniently
to run Oncofuse tool [27] (G). By implementing a Naive
Bayes Network Classifier, Oncofuse identifies gene fusions
that could behave as driver of oncogenic processes and
assigns them a driver score probability (H). Conversely,
Pegasus provides for each fusion a driver score proba-
bility that results from a binary classification algorithm
using gradient tree boosting. The classifier is trained on
a feature space of protein domain annotations and val-
idated tumor fusions (A, second phase). Thus, all the
fusions are labelled with two scores describing their driver
probability.
At the same time, all the fusions selected in (F) are fur-
ther evaluated by considering the biological mechanism
underlying their sequences. Specifically, depending on the
tool responsible for the detection, the gene fusion con-
sensus sequence or the split reads supporting the fusion
are retrieved. For each fusion, four virtual references are
reconstructed, according to the breakpoint coordinates
reported by chimeric transcript discovery tools. These vir-
tual references account respectively for the retention in
the fusion sequence of i) a promoter region in the 5’ gene,
and a 3’ end region in the 3’ gene, ii) a promoter region
in the 3’ gene, and a 3’ end region in the 5’ gene, iii) a
promoter region in both the partner genes and iv) a 3’
end region in both the partner genes. The gene fusion
consensus sequence or the split reads supporting the
fusion (depending on the tool responsible for gene fusion
detection) are then matched against the four different
virtual references. This is done to assess which portions
of the two partner genes are retained in the fusion (I).
Consequently, the structural mechanism underlying the
observed event and the transcriptional potential of the
fusion can be hypothesized. In the following we will define
reliable fusions those fusions accounting for the conser-
vation of a promoter region in the 5’ gene and a 3’ end
region in the 3’ partner gene, or the conservation of both
the promoters in the two fused genes. Indeed, these fusion
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structures are plausible from a biological view point and
could account for high transcription rates.
As last step of the method, fusions with a biologi-
cally reliable structure and/or having a Pegasus and/or
Oncofuse driver probability higher than a fixed threshold
are extracted. These fusions are marked as priority since
reliable and with a potential role in the pathology (L).
Results
FuGePrior tool has been tested on two paired-end RNA-
Seq publicly available datasets from Edgren and colleagues
[15] and Ren and colleagues [18] respectively. The breast
cancer dataset has been downloaded from the Sequence
Read Archive (SRA) with accession code SRP003186,
whereas the second one from the European Nucleotide
Archive (ENA) with accession numbers ERS025221-
ERS025248. The first dataset includes four breast cancer
cell lines (e.g., MCF-7, KPL-4, BT-474 and SK-BR-3) and a
normal breast sample. The latter instead comprises four-
teen primary prostate cancer samples and their matched
adjacent tissues.
Both datasets have been selected since i) reads in
paired-end format allow to run state of the art chimeric
transcript discovery tools which outputs constitute the
input required to perform FuGePrior analysis, ii) they
come with a partial in lab validation, thus allowing
to make considerations concerning the effectiveness of
the proposed approach in prioritizing real fusions, iii)
they include samples from healthy tissues that can
be exploited to implement Filter E of the proposed
pipeline.
Furthermore, one dataset comes from the sequencing of
cancer cell lines, whereas the other from the sequencing of
primary tumor tissues.We exploited this feature to further
discuss FuGePrior results on data from different sources.
The following subsections report on the running param-
eters adopted to analyse breast and prostate cancer
datasets and on FuGePrior results on the same datasets.
Testing procedure
Both paired-end RNA-Seq datsets on which we run
FuGePrior tool have been downloaded in fastq read for-
mat. However, read identifiers must be opportunely for-
matted to perform gene fusion detection. Specifically,
mate_1 and mate_2 (i.e., the two sequenced ends of a
cDNA fragment) need to be labelled with /1 or /2 respec-
tively, according to deFuse specifications. This task has
been executed by an ad-hoc developed script.
As highlighted in the “Implementation” section, deFuse
and ChimeraScan runs are compulsory to perform
FuGePrior analysis. Conversely, users are let free to select
a third chimeric transcript discovery tool according to
their needs. The choice of the third tool is only limited
by the compatibility of its output with Pegasus input
specifications. We run the latest versions of deFuse
(deFuse 0.6.1), ChimeraScan (ChimeraScan 0.4.5) and
MapSplice (MapSplice 2.1.8) [28] with default config-
urations on hg19 reference genome. Furthermore, we
triggered MapSplice run in order to report also on the
so called well annotated fusions. MapSplice output files
have been then formatted in the Pegasus general file
format by an ad-hoc developed script. Two additional
scripts allowed to adapt deFuse and ChimeraScan output
files to Pegasus input requirements. Specifically, deFuse
latest version output has been reformatted according
to deFuse previous version output (compatible with
Pegasus) and ChimeraScan 0-based coordinates have
been converted in 1-based coordinates to be compa-
rable with deFuse and MapSplice results. These two
scripts are provided to users together with FuGePrior
code. Gene fusion lists from deFuse, ChimeraScan
and Mapslice are then processed by Pegasus (latest
version). Pegasus configuration file has been oppor-
tunely modified by specifying the sample identifiers and
the relative tissue of origin. Results from Pegasus run
are then elaborated by FuGePrior as detailed in the
“Implementation” section. As already mentioned,
FuGePrior run can be easily and highly customized to
answer user needs. First of all, by modifying FuGePrior
configuration file, users can select which unannotated
genes (or not interesting genes) have to be removed from
the final list of candidates. We performed the analyses
reported in this manuscript by removing all the fusions
involving genes which names begin with one of the
following strings AC0, AC1, AK, AD0, AL0, AL1, AL5,
AL6, AP0, NCRNA, LL22NC, CTC, RNASE, HLA, BC0,
AL6, BC1, LOC. Similarly, the tissue of origin of the
tumor can be specified in the configuration file. Thus,
allowing the generation of an ad-hoc formatted input
file for Oncofuse run. EPI (i.e., epithelial origin), HEM
(i.e., hematological origin), MES (i.e., mesenchymal ori-
gin) and AVG (i.e., average expression, if tissue source
is unknown) are the labels that users can specify in
FuGePrior configuration file. Our experiments have been
performed by specifying MES string in the configuration
file and using Oncofuse latest version (Oncofuse 1.0.9).
FuGePrior evaluates the biological mechanism at the
basis of gene fusion structure by reconstructing four
different virtual references that account for the retention
in the gene fusion of different portions of the partner
genes. These virtual references are later matched against
ChimeraScan split reads and deFuse/MapSplice consen-
sus sequences to determine the gene fusion structure.
Users can specify the length of the four reconstructed
virtual references and the minimum overlap between
reads/consensus sequence (depending on the tool) and
virtual reference, required to label the fusion with a spe-
cific gene structure information. The analyses performed
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on breast and prostate cancer datasets consider a virtual
reference length of 30 bp and a minimum overlap to
correctly label a fusion equal to 15 bp. Finally, users can
fix the driver score probability threshold exploited by
Filter L. We selected 0.7 as threshold in the proposed
analyses.
Breast cancer dataset
ChimeraScan detected 55, 27, 197 and 132 fusions in
MCF-7, KPL-4, BT-474 and SK-BR-3 cell lines, respec-
tively. Conversely, deFuse found 39, 42, 319 and 231
chimeric transcripts in the same cell lines. A very reduced
number of fusions is instead reported by MapSplice in the
different cell lines. This number ranges from 4 fusions in
KPL-4 cell line to 36 in BT-474. Furthermore, the same
tools identified 41, 60 and 1 fusions in the normal breast
sample.
The barchart of Fig. 2 describes, for the breast cancer
cell lines under investigation, the impact of the filtering
stages implemented within FuGePrior on the number of
retained gene fusions.
The collapsing of the fusions performed by Filter C
accounted for a reduction in the amount of reported
fusions that varies from a minimum of 2.8% in SK-
BR-3 to a maximum of 7.6% in MCF-7. We identi-
fied 2 fusions (BCAS4/BCAS3 and UNC45B/DLG2), 1
fusion (UNC45B/DLG2), 3 fusions (MT-ND6/MT-ATP-6,
KLF15-AL121656.4 and THRA-AC090627.1) and 1 fusion
(UNC45B/DLG2) reported by deFuse in MCF-7, KPL-4,
BT-474 and SK-BR-3 cell lines respectively with different
supporting reads. None chimeric transcripts are instead
reported by ChimeraScan and MapSplice as supported by
different reads. Furthermore, we deeply investigated the
agreement among tools on gene fusion discovery, pointing
out a poor well known overlap among their results. Specif-
ically, only 2, 1, 11 and 8 fusions are identified by both
ChimeraScan and deFuse in MCF-7, KPL-4, BT-474 and
SK-BR-3 respectively. 0, 0, 1 and 0 fusions are reported by
deFuse and MapSplice in the same cell lines. 3, 0, 1 and 1
fusions have been found by both ChimeraScan and Map-
Splice. Finally, only 1 (BCAS4/BCAS3), 1 (BSG/NFIX),
2 (STX16/RAE1, RAB22A/MYO9B) and 0 fusions have
been reported by all the tools within the considered breast
cancer cell lines. Figure 3 shows the percentage num-
bers of fusions reported, in the different cell lines, by the
deFuse, ChimeraScan and MapSplice tools or combina-
tions among them. For visualization reasons, values are
rounded to the first decimal place.
The removal of fusions involving unannotated partner
genes (Filter D) produced a conspicuous decrease in the
number of events to be considered in the next steps of
the workflow. Indeed, 32 (32.9% of reduction), 20 (28.9%
of reduction), 107 (20.1% of reduction) and 99 (26.2% of
reduction) fusions have been respectively deleted from
the set of chimeras in MCF-7, KPL-4, BT-474 and SK-
BR-3 cell lines. Results are little impacted by Filter E.
Indeed, this filter accounted for the removal of 1, 0, 6
and 2 gene fusions in MCF-7, KPL-4, BT-474 and SK-
BR-3 cell lines respectively. Conversely, a huge amount
of fusions is filtered out because not supported by split
reads (Filter F). Indeed, only 48, 37, 317 and 209 fusions
are supported by at least a split read in MCF-7, KPL-4,
BT-474 and SK-BR-3 cell lines. Furthermore, we investi-
gated the amount of fusions that, after Filter F application,
Fig. 2 FuGePrior filtering in Breast Cancer dataset. Each group of bars reports, for the different breast cancer cell lines on x-axis, on the number of
fusions retained after the application of the different filtering stages implemented by FuGePrior pipeline
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Fig. 3 Consensus among tools in Breast Cancer dataset. Subfigures 3a, 3b, 3c and 3d report for MCF-7, KPL-4, SK-BR-4 and BT-474 respectively on the
percentage amounts of fusions identified by the three considered gene fusion discovery tools or combinations among them
presents a reliable (according to our previous definition)
gene fusion structure. We found that 25 out of 48 fusions
in MCF-7 cell line, 18 out of 37 in KPL-4, 97 out of 317
in BT-474 and 76 out of 209 in SK-BR-3 account for the
retention of a promoter sequence in the 5’ partner gene
and for a 3’ end region in the 3’ gene. Furthermore, 9,
6, 32 and 28 fusions in the same breast cancer cell lines
retained a promoter region in both the partner genes. To
be as thorough as possible, we report in the piecharts
of Fig. 4 on the percentage number of fusions character-
ized by the different analysed gene fusion structures. For
visualization reasons, values are rounded to the first dec-
imal place. In the legend, prom-end and prom-prom refer
to those fusions that we defined as biologically reliable
since accounting for a promoter sequence in the 5’ part-
ner gene and for a 3’ end region in the 3’ partner gene
or for both promoters retained in the fusion. Conversely,
end-prom label refers to fusions characterized by a pro-
moter sequence in the 3’ partner gene and a 3’ end region
in the 5’ partner gene. end-end label refers to fusions
that retain a 3’ gene end region in both partner genes.
Finally, NoMatch label is relative to fusions for which we
did not find a match on the four reconstructed virtual
references.
The analysis of Pegasus and Oncofuse driver scores
(Filter A, second phase and FilterH) led to the identifica-
tion of 6, 4, 28 and 27 fusions in MCF-7, KPL-4, BT-474
and SK-BR-3 cell lines for which one or both tools pro-
vided a driver score greater than 0.7. Among these fusions,
6 out of 6 in MCF-7, 3 out of 4 in KPL-4, 21 out of 28 in
BT-474 and 23 out of 27 in SK-BR-3 have a biologically
reliable structure.
By implementing Filter L, fusions with a driver score
greater than 0.7 and/or characterized by a plausible bio-
logical mechanism are selected andmarked as reliable and
with a potential role into the pathology. As a result, 34, 25,
137 and 111 fusions respectively in MCF-7, KPL-4, BT-
474 and SK-BR-3 belong to the final list of priority fusions.
These values account for a reduction in the number of
fusions output of chimeric transcript discovery tools equal
to 66.6, 64.4, 75 and 70.9% in MCF-7, KPL-4, BT-474
and SK-BR-3 respectively. For completeness we report in
Additional file 1: (S1) on the consensus among chimeric
transcript discovery tools pointed out in the final list of
FuGePrior priority fusions.
The lack of not-synthetic datasets with a complete gene
fusion validation, makes the assessment of the perfor-
mance of gene fusion detection and prioritization tools
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Fig. 4 Gene fusion structures in Breast Cancer dataset. Subfigures 4a, 4b, 4c and 4d report for MCF-7, KPL-4, SK-BR-4 and BT-474 respectively on the
average percentages of fusions characterized by the five different fusion structures we investigated after FuGePrior Filter F application
very challenging, in terms of both sensitivity and speci-
ficity. However, for some datasets as the one under inves-
tigation, a partially validation of the fusions is available.
Specifically, the study by Edgren reports on 3, 3, 11 and
10 fusions identified respectively in MCF-7, KPL-4, BT-
474 and SK-BR-3 cell lines. In absence of a full validated
dataset, the best that can be done to evaluate results
from the novel in-silico procedure we propose, consists
in comparing gene fusions that we found to be priority
after FuGePrior analysis with those previously validated
by Edgren and colleagues.
These results are reported in Additional file 1: (S2).
Concerning MCF-7 all the 3 validated fusions have been
prioritized by the proposed approach. Specifically, all
the fusions are characterized by a biologically reliable
structure.
All the validated fusions fromKPL-4 cell line, passed the
filtering stages implemented in the proposed pipeline. 2
out of 3 fusions account for both a reliable biological struc-
ture and high driver scores, 1 out of 3 fusion satisfies only
the reliability criterion.
Ten out 11 validated fusions in BT-474 cell line are
reported as output of the implemented methodology. In
particular, 5 have been retained since satisfying both the
rules (driver scores and biological mechanism), whereas 5
because characterized by a biologically reliable structure.
The only missed fusion has been removed since not sup-
ported by split reads.
Finally, 9 out 10 chimeric transcripts have been detected
as priority by our methodology in SK-BR-3 cell line. 3 have
high driver scores and plausible structures, whereas the
remaining satisfy the second criterion. Only 1 validated
fusion has not been reported since not identified by gene
fusion detection tools.
Prostate cancer dataset
ChimeraScan, deFuse andMapSplice reported on an aver-
age number of fusions in the 14 samples from Ren dataset
respectively equal to 91, 1465 and 11. Even in this dataset,
chimeric transcript discovery tools rarely agree on the
identified gene fusions. In details, the mean number of
fusions identified by both ChimeraScan and deFuse is
equal to 1, whereas no shared fusions are in average
reported for the other combinations of algorithms. The
complete analysis is reported in Additional file 1: (S3). The
barcharts of Fig. 5 describe, for the different tumor sam-
ples included in prostate cancer dataset, the impact of the
filtering stages implemented by FuGePrior on the num-
ber of retained gene fusions. Filter C is responsible for the
removal of a mean number of fusions equal to 7 across
the 14 samples under investigation, with a maximum of 14
fusions discarded in Sample 12T. The impact of Filter D
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Fig. 5 FuGePrior filtering in Prostate Tumor dataset. Each group of bars reports, for the different prostate cancer samples on x-axis, on the number of
fusions retained after the application of the different filtering stages implemented by FuGePrior pipeline
for unannotated fusion removal, varies depending on the
considered sample with aminimum reduction observed in
Sample 4T (10.8%) and a maximum occurring in Sample
5T (16.5%).
Ren dataset includes, for each tumor sample, the adja-
cent normal tissue, allowing the application of Filter E that
acts by removing fusions shared by reactive samples. We
observed a maximum percentage decrease in the number
of fusions (24.7%) in Sample 3T, that shares 60 fusions
with the adjacent normal tissue. The removal of fusions
not supported by split reads, performed by Filter F, is
once a time more evident in Sample 3T with a percentage
reduction equal to 8.7%. Furthermore, we investigated the
biological mechanism at the basis of the fusions retained
after Filter F application. The piechart of Fig. 6 reports
on the average percentages of fusions characterized by the
different investigated gene fusion structures. As it is pos-
sible to note from the graph a not negligible percentage of
fusions is characterized by a biologically not reliable gene
structure.
The greater impact in gene fusion number reduction is
produced by Filter L. As already explained, the filter works
by evaluating the driver score probabilities provided by
Oncofuse and Pegasus tools and the biological mechanism
at the basis of the fusion. Its application accounted for
an average percentage reduction in the number of output
fusions of about 46.4% across the considered samples. For
completeness, we report in Additional file 1: (S3) on the
agreement among ChimeraScan, deFuse and MapSplice
tools in FuGePrior output fusion identification.
Finally, we focused on the 5 validated gene fusions from
Ren and colleagues to check for their presence in the
final list of priority gene fusions from FuGePrior. Results
are reported in Additional file 1: (S4). In detail, USP9Y-
TTTY15 fusion, identified by Ren in Samples 4T and 6T
and 12T is not present in FuGePrior output relative to
these samples. This is because none of the chimeric tran-
script discovery tools reported on it. It is worth noting that
FuGePrior prioritized 3 different reciprocal gene fusions
(TTTY15-USP9Y). Two of them occurring in Sample 4T
and the other in 6T with different breakpoints. USP9Y-
TTTY15 fusion has been identified for the first time in
Fig. 6 Gene fusion structures in Prostate Tumor dataset. The piechart
reports on the average percentages of fusions characterized by the
five different fusion structures we investigated after FuGePrior Filter F
application
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the experiments performed by Ren and its occurrence in
several samples allows to hypothesize a role of the fusion
in cancer development. The well known prostate cancer
fusion TMPRSS2-ERG has been validated in Samples 1T,
5T and 13T. FuGePrior correctly prioritized this fusion
in the same samples with breakpoints on hg19 corre-
sponding respectively for 5’ gene and 3’ gene to chr21:
42880008 and chr21: 39817544. The fusion has been iden-
tified by both ChimeraScan and deFuse in Sample 5T,
whereas only ChimeraScan reported on it in Samples 1T
and 13T. The fusion involving TMPRSS2 and ERG genes
occurr between exon 1 of the first partner and exon 4
of the second. However, note that several other break-
points on these genes have been recently described [29].
Furthermore, additional analyses performed by Ren and
colleagues on 54 prostate tumor samples confirmed the
presence of TMPRSS2-ERG fusion in Chinese popula-
tion at lower frequency (about 20%) with respect to that
observed in Caucasian patients [30]. RAD50-PDLIM4
fusion has been found, confirming Ren results, in Sam-
ple 10T with fusion breakpoints on hg19 corresponding
to chr5:131945088 and chr5:131598302. The three fusion
discovery tools agreed on its identification within Sam-
ple 10T. The last two validated fusions, SDK1-AMACR in
Sample 7T and CTAGE5-KHDRBS3 in Sample 10T, are
not reported as output of FuGePrior run due to the fact
that they are not present in the output from chimeric tran-
script discovery tools. Concerning CTAGE5-KHDRBS3,
SDK1-AMACR, and RAD50-PDLIM4 gene fusions Ren
proven their occurrence also in the additional 54 prostate
tumor samples analysed (with percentages ranging from
24 to 37%). Additional evidences for their occurrence in
prostate Chinese tumor samples are discussed in [31].
Discussion
Chimeric transcript discovery tools generally provide as
output huge lists of poorly overlapping gene fusions.
Higher the coverage of the samples under investigation,
higher the number of reported candidate fusions.We con-
sidered in this work two datasets. The first from breast
cancer cell lines characterized by quite reduced coverage
(number of reads ranging from a minimum of 13600332
reads in KPL-4 cell line to a maximum of 42861028 in SK-
BR-3), and the other from prostate primary tumor samples
that includes about 1860097798 reads with a maximum
number of reads equal to 150304440 in Sample 13T and a
minimum of 43908581 reads in Sample 3T. The not com-
parable dimensions of the two datasets explain the large
difference in the number of fusions reported by chimeric
transcript discovery tools in the considered datasets. Fur-
thermore, it is worth noting that the very reduced number
of fusions identified by MapSplice was expected. Indeed,
we pointed out the same trend in analyses we performed
on private datasets from different pathologies. However,
for both datasets, the huge number of fusion candidates
from chimeric transcript discovery tools makes unfea-
sible the in lab validation of all these predictions, thus
calling for ad-hoc strategies to shrink down the number
of fusions, focusing on a reduced set of highly reliable
fusions.
As pointed out in the “Results” section, chimeric tran-
script discovery tools rarely agree on the provided pre-
dictions. Furthermore, in few cases they identify the same
fusion using different reads. This explains the derisory
impact of Filter C in reducing fusion numbers.
A more evident impact in gene fusion removal is due
to Filter D implementation. The high number of fusions
involving unannotated genes leads to reflect on the fact
that there is still much to be done. Indeed, even if these
genes are nowadays only partially known, they could have
an active role in cancer processes. Filter E application
produced different results in the two considered datasets.
Indeed, it is responsible for an average reduction in the
number of fusions equal to 0.9% and 9% in breast cancer
cell lines and primary prostate tumor data respectively.
These results can be explained by the fact that the reac-
tive samples of the second dataset are “more specific”
since match the adjacent prostate tumor tissue. Thus, they
could account for higher similarity with tumor samples
and so for a greater number of fusions shared with them.
The removal of those fusions not supported by split reads
(Filter F) produced a relevant decreasing in the num-
ber of output candidates. All the removed fusions are
from ChimeraScan tool, since deFuse and MapSplice do
not report predictions with 0 split reads. The absence of
split reads accounts for the incapability in reconstruct-
ing a fusion sequence from chimeric transcript detection
tool outputs unless additional mapping and processing
steps. However, it should be considered that these addi-
tional steps are prone to errors and could lead to the
identification of false positive fusions.
The analysis of gene fusion structure (I) pointed out,
in both the datasets, a not net prevalence of transcripts
having a biologically reliable configuration. Indeed, as
summarized in Figs. 4 and 6, respectively for breast and
prostate datasets, a relevant number of fusions from
chimeric transcript discovery tools accounts for the struc-
tures we labelled as end-end and end-promoter. This find-
ing should be deeply investigated with in lab experiments
to assess if these fusions are false positive predictions
or not and, in case of positive results, to evaluate the
transcriptional potential of such aberrations. As expected,
Oncofuse and Pegasus tools (A, second phase and H)
produced little overlapping results because of the differ-
ent classification methods they adopt. For instance, they
agreed in the assignment of a driver score greater than
0.7 for 1, 2, 4, and 2 fusions in MCF-7, KPL-4, BT-
474 and SK-BR-3 cell lines respectively. On average, 16
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fusions are prioritized with a driver score greater than
0.7 by both Oncofuse and Pegasus in the 14 Samples
from prostate cancer. We considered the union of high
scored fusions from the tools to be as exhaustive as pos-
sible. Finally, the choice to focus in the last phase of the
pipeline, on the union set of high scored and biologically
reliable fusions (Filter L), has been made, once a time, to
be conservative, thus avoiding loss of sensitivity. Indeed,
in previous analyses on Burkitt lymphoma samples we
validated through PCR experiments fusions characterized
by a non reliable fusion structure but having high driver
scores, while in AML samples we were able to confirm in
lab fusions with a reliable structure but low driver scores.
Concerning the validated fusions, it is worth noting that
only 2 out 3 fusions in MCF-7 have been identified by
two tools, whereas none has been reported by all chimeric
transcript discovery tools. 1 out of 3 fusions in KPL-4 has
been reported by all the tools, 1 by two tools. 2 out of 10
and 2 out of 9 fusions in BT-474 and SK-BR-3 respectively
have been identified by two tools. A unique fusion in both
these last cell lines has been reported by all the tools. Rela-
tively to the two validated fusions confirmed by FuGePrior
in prostate dataset, TMPRSS2-ERG has been identified
by both ChimeraScan and deFuse in Sample 5T, whereas
only ChimeraScan reported on it in Samples 1T and 13T.
Furthermore, RAD50-PDLIM4 fusion has been found in
Sample 10T by all the fusion discovery tools. These results
confirm the need for considering the output from more
than a tool when performing gene fusion discovery. Fur-
thermore, the presence of validated fusions having only 1
supporting split read confirms the importance of avoiding
filtering stages to remove chimeric transcripts supported
by few reads.
To summarize, FuGePrior analysis accounted for a
reduction in the number of fusions from chimeric tran-
script discovery tools of 66.6, 64.4, 75 and 70.9% respec-
tively inMCF-7, KPL-4, BT-474 and SK-BR-3 cell lines. An
average reduction in the number of fusions equal to 46.4%
has been instead reported for prostate cancer dataset.
Furthermore, 25 out of the 27 breast cancer fusions pre-
viously in lab confirmed, have been correctly labelled as
priority by our pipeline. It is worth noting that 1 of the
2 remaining fusions was not detected by chimeric tran-
script discovery tools and then it was not given in input
to the proposed pipeline. Thus, in synthesis, the proposed
method labelled as priority 25 out of 26 validated fusions.
Similarly, 2 out of 5 validated fusions in prostate cancer
have been correctly prioritized by FuGePrior. Even in this
case the other 3 fusions were not reported by chimeric
transcript discovery tools.
Conclusions
In this work, we propose a methodological approach and
tool named FuGePrior to shrink down the union set list
of candidates from different chimeric transcript discov-
ery tools, thus focusing on a reduced number of reliable
fusions with a potential role in the pathology. This novel
pipeline includes a series of modules and filtering steps
designed by considering both chimeric transcript discov-
ery and annotation tool outputs and state of the art liter-
ature concerning gene fusions. FuGePrior is implemented
in Python programming language and its run can be
widely triggered by users depending on their needs. The
proposedmethodology has been tested on two paired-end
RNA-Seq publicly available datasets from breast cancer
cell lines and prostate primary tumors. Results accounted
for a reduction in the number of fusions output of
chimeric transcript discovery tools that ranges from 64.4
to 75% in breast cancer dataset and from 37 to 65% in the
prostate one. Furthermore, both datasets come with a par-
tial validation that allowed us to assess the performance of
the proposed approach in correctly prioritizing real gene
fusions. Specifically, 25 out of 27 validated fusions have
been correctly prioritized in breast cancer dataset. Fur-
thermore, 2 out of 5 validated fusions in prostate tumor
dataset have been reported as output of FuGePrior run. It
is worth noting that globally 4 out of 5 validated fusions
that have not been prioritized by FuGePrior were not
given in input to the pipeline because not identified by
chimeric transcript discovery tools. Analyses performed
on private AML, Acute Lymphoblastic Leukemia (ALL),
Burkitt Lymphoma and Mastocytosis samples confirmed
the great potential of this methodological approach in
providing biologists with a limited number of reliable
fusions.
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